Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Completed · Phase 2

Conditions studied: Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma

In brief

The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.

Key facts

Study ID

NCT01506596

Run by

Vector Oncology

People needed

42

Starts

2012-03-01

Expected to finish

2016-03-01

Last updated by the study team

2017-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent.
• Age > or = to 18 years.
• Histologically or cytologically confirmed high- or intermediate-grade liposarcoma (allowed subtypes include liposarcoma dedifferentiated, myxoid/round cell, pleomorphic, mixed-type, or not otherwise specified).
• Surgically unresectable or metastatic disease.
• Any number of prior treatment treatment regimens, including treatment naive subjects.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1. Subjects must have documented disease progression within the past 6 months.
• Adequate organ system function determined within 14 days prior to first dose of study treatment.
• Left ventricular ejection fraction (LVEF) > 50% of the institutional LLN within 28 days prior to the first dose of study treatment.
• Females must be of either non-child bearing potential or have a negative pregnancy test within 7 days prior to the first dose of study treatment.

You may not qualify if…

• Well differentiated liposarcoma.
• Prior treatment with tyrosine kinase inhibitors (TKIs) or vascular endothelial growth factor (VEGF) inhibitors.
• Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).
• History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off steroids and anti-seizure medication for 6 months prior to first dose of study drug
• Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding.
• Clinically significant GI abnormalities that may affect absorption of investigational product.
• Presence of uncontrolled infection.
• Corrected QT interval > 480 msecs using Bazett's formula.
• History of certain cardiovascular conditions within the past 6 months.
• Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg or diastolic blood pressure > or = 90 mmHg].
• History of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep vein thrombosis within the past 6 months.
• Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
• Evidence of active bleeding or bleeding diathesis.
• Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.
• Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.
• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
• Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug, whichever is longer, prior to the first dose of study drug and for the duration of study treatment.
• Radiation therapy, minor surgery, tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.
• Administration of any non-oncologic investigational drug within 30 days or five half-lives (whichever is longer) prior to receiving the first dose of study drug.
• Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.
• Known immediate or delayed hypersensitivity reaction to idiosyncrasy to drugs chemically realted to pazopanib or excipients that contraindicates participation.

Where it is running

• Sarcoma Oncology Center — Santa Monica, California, United States
• Washington Cancer Institute — Washington D.C., District of Columbia, United States
• Kootenai Cancer Center — Post Falls, Idaho, United States
• Oncology Specialists, SC — Niles, Illinois, United States
• University of Iowa — Iowa City, Iowa, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Pennsylvania Oncology Hematology Associates — Philadelphia, Pennsylvania, United States
• West Clinic — Memphis, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.